U.S. Markets closed

Soligenix awarded BARDA contract valued up to $26.3M

Soligenix announced that it has been awarded a contract valued at up to $26.3M by the US Department of Health and Human Service's Biomedical Advanced Research and Development Authority. The contract is for the advanced preclinical and manufacturing development of OrbeShield as a MCM for the treatment of gastrointestinal acute radiation syndrome. The potential five year contract contains a two year base period, with two contract options that would extend the contract an additional three years.